NDAC meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA's Pulmonary & Allergy, Dermatologic & Ophthalmologic Drugs Advisory Committees will join NDAC in deliberations on OTC switch of Schering-Plough's Claritin (loratadine). April 22 public meeting will focus on chronic idiopathic urticaria as an OTC indication (1"The Tan Sheet" March 18, 2002, In Brief). Committees also will meet in closed-door session April 23. Individuals wishing to speak at April 22 meeting must file written submissions by April 12...
You may also be interested in...
NDAC meeting
Committee will meet in closed session April 23 to discuss "confidential trade secret information" with FDA and to receive an update from agency's drug review division. One day earlier, NDAC will consider Schering-Plough's three switch NDAs for non-sedating antihistamine Claritin (loratadine); the "primary purpose" of the April 22 meeting is to discuss chronic idiopathic urticaria as an OTC indication, FDA says...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.